French
DeutschLinvoseltamab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | CD3 and BCMA |
| Clinical data | |
| Other names | REGN5458, REGN-5458 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6455H9955N1721O2039S47 |
| Molar mass | 145800.47 g·mol−1 |
Linvoseltamab, is an experimental anti-cancer medication intended for the treatment of people with relapsed and refractory multiple myeloma.[1][2] Linvoseltamab is a bispecific monoclonal antibody that targets CD3 and BCMA (TNFRSF17).[1]
Society and culture
[edit]Legal status
[edit]In February 2025, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product Lynozyfic, intended for the treatment of people with relapsed and refractory multiple myeloma who have received at least three prior therapies.[1] The applicant for this medicinal product is Regeneron Ireland DAC.[1]
Names
[edit]Linvoseltamab is the international nonproprietary name.[3]
References
[edit]- ^ a b c d "Lynozyfic EPAR". European Medicines Agency (EMA). 27 February 2025. Retrieved 6 March 2025. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ Avigan ZM, Rattu MA, Richter J (February 2025). "An evaluation of linvoseltamab for treatment of relapsed/refractory multiple myeloma". Expert Opinion on Biological Therapy: 1–8. doi:10.1080/14712598.2025.2465825. PMID 39923122.
- ^ World Health Organization (2022). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 88". WHO Drug Information. 36 (3). hdl:10665/363551.
External links
[edit]- "Linvoseltamab (Code C158504)". NCI Thesaurus.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |